Literature DB >> 23399411

Anti-C1q antibodies and systemic lupus erythematosus in the Tunisian population.

B Trad1, H Ben Hassine, M Khalifa, N Idriss, F Slama, F Bahri, C Laouani Kechrid, J Boukadida, R Sghiri.   

Abstract

OBJECTIVES: The presence of a wide variety of autoantibodies is a characteristic feature of systemic lupus erythematosus (SLE). Although non-specific, anti-complement C1q (anti-C1q) were shown to correlate with the occurrence of active nephritis. The present study aimed to investigate the prevalence of anti-C1q in Tunisian SLE patients and their association with clinical manifestations, especially renal involvement. PATIENTS AND METHODS: IgG anti-C1q antibodies were assessed by Elisa in 98 SLE patients, 55 patients with rheumatoid arthritis (RA) and 65 healthy individuals (HI).
RESULTS: Anti-C1q were found in 53 (54.1%) patients with SLE, three (5%) patients with RA and six (9.3%) HI. Among the 65 patients with renal involvement, anti-C1q were present in 35 (53.8%) patients. There was no significant association between anti-C1q and renal or extrarenal manifestations. In addition, there was no correlation between anti-C1q titer and SLEDAI index. Anti-C1q were significantly associated with anti-nucleosome (P=0.001), anti-Sm (P=0.01) and a low C4 level (P=0.046). Concomitant presence of anti-C1q and anti-dsDNA antibodies was not associated with renal manifestations.
CONCLUSION: Our study shows that prevalence of anti-C1q was comparable with that previously reported in Caucasian populations. These antibodies were associated with a low C4 level. However, there was no association between anti-C1q and renal involvement or severity of nephritis.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23399411     DOI: 10.1016/j.patbio.2013.01.007

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  5 in total

1.  Evaluation of Endothelial Cell Adhesion Molecules and Anti-C1q Antibody in Discriminating between Active and Non-Active Systemic Lupus Erythematosus.

Authors:  Hasni Mahayidin; Nurul Khaiza Yahya; Wan Syamimee Wan Ghazali; Asmahan Mohd Ismail; Wan Zuraida Wan Ab Hamid
Journal:  Malays J Med Sci       Date:  2016-05

2.  Anti-C1q Antibody is Associated with Renal and Cutaneous Manifestations in Asian Indian Patients with Systemic Lupus Erythematosus.

Authors:  Jayakanthan Kabeerdoss; Nikhil Gupta; Sandhya Pulukool; Hindhumathi Mohan; Gowri Mahasampath; Debashish Danda
Journal:  J Clin Diagn Res       Date:  2017-03-01

3.  The Usefulness of Endothelial Cell Adhesion Molecules and Anti-C1q Antibody in Monitoring Systemic Lupus Erythematosus Disease Activity.

Authors:  Hasni Mahayidin; Nurul Khaiza Yahya; Wan Syamimee Wan Ghazali; Asmahan Mohd Ismail; Wan Zuraida Wan Ab Hamid
Journal:  Int Sch Res Notices       Date:  2014-10-29

4.  Association between the Presence of Autoantibodies Targeting Ficolin-3 and Active Nephritis in Patients with Systemic Lupus Erythematosus.

Authors:  Maëlle Plawecki; Elise Lheritier; Giovanna Clavarino; Noémie Jourde-Chiche; Saber Ouili; Stéphane Paul; Evelyne Gout; Françoise Sarrot-Reynauld; Nathalie Bardin; Pierre-Yves Boëlle; Laurent Chiche; Laurence Bouillet; Nicole M Thielens; Jean-Yves Cesbron; Chantal Dumestre-Pérard
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

5.  Anti-C1q antibodies in systemic lupus erythematosus.

Authors:  A-M Orbai; L Truedsson; G Sturfelt; O Nived; H Fang; G S Alarcón; C Gordon; Jt Merrill; P R Fortin; I N Bruce; D A Isenberg; D J Wallace; R Ramsey-Goldman; S-C Bae; J G Hanly; J Sanchez-Guerrero; A E Clarke; C B Aranow; S Manzi; M B Urowitz; D D Gladman; K C Kalunian; M I Costner; V P Werth; A Zoma; S Bernatsky; G Ruiz-Irastorza; M A Khamashta; S Jacobsen; J P Buyon; P Maddison; M A Dooley; R F Van Vollenhoven; E Ginzler; T Stoll; C Peschken; J L Jorizzo; J P Callen; S S Lim; B J Fessler; M Inanc; D L Kamen; A Rahman; K Steinsson; A G Franks; L Sigler; S Hameed; N Pham; R Brey; M H Weisman; G McGwin; L S Magder; M Petri
Journal:  Lupus       Date:  2014-08-14       Impact factor: 2.911

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.